Therapeutics Company Reveals Positive Data From Cancer Clinical Study
CX-904 showcased a favorable safety profile, a critical factor in the administration and monitoring of patients in outpatient settings.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment. The findings, characterized by a favorable safety profile and confirmed anti-cancer activity, herald a new dawn in the treatment of EGFR-positive cancers, offering hope where conventional therapies have faltered. $CytomX(CTMX.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
nice Elephant_6987 : So with good news it tanks?
71756907 : From what i’ve learned its their dilution that may have caused the fall, they had certain limits of share price where they were granted additional funding of three levels which where hit in the after hours of the report. This may have spooled the investors.
nice Elephant_6987 71756907: Yep definitely looks that way.thanks